VildagliptinThird Party Manufacturing in India

Vildagliptin is a potent, selective inhibitor of dipeptidyl peptidase-4, the enzyme responsible for degrading incretin hormones such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. By blocking DPP-4, vildagliptin increases the circulating levels of active GLP-1 and GIP. These incretin hormones stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning they only promote insulin release when blood glucose is elevated. Additionally, higher GLP-1 levels suppress glucagon secretion from alpha cells, further reducing hepatic glucose production. This glucose-dependent mechanism means vildagliptin has a very low risk of causing hypoglycemia. Unlike some other DPP-4 inhibitors, vildagliptin also shows a unique effect on improving pancreatic beta-cell function over time, which may slow disease progression in type 2 diabetes. It is effective at lowering both fasting and postprandial glucose levels, making it suitable for once-daily or twice-daily dosing depending on the treatment regimen.

Therapeutic Uses

Vildagliptin is indicated for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy in patients inadequately controlled by diet and exercise alone, particularly when metformin is contraindicated or not tolerated. It is also used in dual combination therapy with metformin, a sulfonylurea, or a thiazolidinedione, and as triple combination therapy with metformin plus a sulfonylurea when prior dual therapy does not provide adequate glycemic control.

• Type 2 Diabetes Monotherapy: For patients who cannot take metformin due to contraindications or intolerance.
• Dual Combination Therapy: With metformin for additive glycemic improvement.
• Combination with Sulfonylurea: For patients who need additional HbA1c reduction.
• Triple Therapy: As part of a multi-drug regimen for advanced disease management.

Why Manufacturers Choose Vildagliptin

Vildagliptin is a high-volume antidiabetic molecule in the Indian pharmaceutical market, with strong demand driven by the country's large diabetic population and the growing preference for DPP-4 inhibitors over older sulfonylurea-based therapies. The molecule offers Indian manufacturers an opportunity to serve both the domestic branded formulation market and export channels to regulated markets. Its established safety profile, dosing flexibility, and compatibility with metformin-based combinations make it a preferred choice for PCD franchise partners and institutional buyers alike.

This makes Vildagliptin one of the most sought-after DPP-4 inhibitors for third party manufacturing in India.